WHIPPANY, N.J.
ISI, a provider of software and services for the life sciences industry, announced that it has acquired Apyx, Inc. The merger adds to ISI’s growing professional services business and enhances the company’s range of offerings in submissions management and outsourcing. The two companies’ shared commitment to customer service and responsiveness make the merger a fit.
ISI currently provides 13 out of the top 20 pharmaceutical companies with ongoing, repeat services. Over the last decade, the company has helped biopharmaceutical companies all over the world bring dozens of therapies through regulatory approval to patients in need. The acquisition helps ISI strengthen its capabilities to offer clients a mix of process, technology, data and operational services that respond to today’s complex submission environment.
“With ISI’s deep resources and expertise in Europe and Asia, we will be able to address the diverse range of submission requirements across the globe," said Ken VanLuvanee, CEO, President and Founder of Apyx, Inc.
ISI makes the acquisition at a time of flux for the pharmaceutical industry. In the wake of transformational new regulations and a host of economic and competitive factors, life sciences firms are dealing with a complex global marketplace they have never seen before. Diverse and ever-changing regulatory standards across regions, the need to expand into emerging markets, and increasing pressure to collaborate with partners and oversee local operations are all contributing to the new era of unparalleled complexity.
With the acquisition of Apyx, ISI will deliver more efficient and standardized processes and systems, enable operational alignment around the globe, and facilitate a more effective exchange of information to help clients navigate these new challenges.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.